Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03692325
Recruitment Status : Recruiting
First Posted : October 2, 2018
Last Update Posted : January 24, 2019
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Glenn J. Hanna, Dana-Farber Cancer Institute

Brief Summary:
This research study is studying an immunotherapy drug, as a possible treatment for oral proliferative verrucous leukoplakia (OPVL).

Condition or disease Intervention/treatment Phase
Leukoplakia, Oral Drug: Nivolumab Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug or combination of drugs to learn whether it works in treating a specific disease. "Investigational" means that the drug/s is being studied.

The purpose of this study is to evaluate effectiveness (how well the drug works) of nivolumab in treating OPVL and or prolonging the onset of possible malignancy.

Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells. Nivolumab has been demonstrated to activate the immune system to attack cancer cells in participants with different types of cancers. OPVL has a high risk for turning into cancer and the investigators are testing if nivolumab may help to shrink the white lesions in the participant's mouth and reduce cancer risk.

In November 2016, the Food and Drug Administration (FDA) approved nivolumab for the treatment of participants with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Squamous cell carcinoma is the kind of cancer that OPVL can transform into.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
Actual Study Start Date : December 5, 2018
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : June 30, 2024


Arm Intervention/treatment
Experimental: Nivolumab
  • Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle
  • Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent
Drug: Nivolumab
Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
Other Name: Opdivo




Primary Outcome Measures :
  1. Best Overall Response Rate [ Time Frame: 2 years ]
    Best response recorded from study registration until the disease progression


Secondary Outcome Measures :
  1. Quality of Life (QOL) [ Time Frame: 2 years ]
    Questionnaires

  2. Evaluate safety and toxicity (Adverse Events and Serious Adverse Events) [ Time Frame: 2 years ]
    Adverse Events and Serious Adverse Events will be recorded

  3. Evaluate the time to the next surgery for a head and neck malignancy [ Time Frame: 2 years ]
    Time to the next surgery for a head and neck malignancy

  4. Estimate Cancer Free Survival (CFS) from the time of study registration [ Time Frame: 2 years ]
    Cancer Free Survival at 2 years from study registration

  5. Estimate Overall Survival (OS) from the time of study registration [ Time Frame: 2 years ]
    Overall Survival at 2 years from study registration

  6. Characterize distinct tumor and circulating immunophentoypes (biomarkers in biopsy and blood samples) [ Time Frame: 2 years ]
    Explore biomarkers in biopsy and blood samples



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must have histologically confirmed oral proliferative verrucous leukoplakia (OPVL), as defined by: multifocal lesions (≥ 2) or contiguous lesions ≥ 3 cm or a single lesion ≥ 4 cm in largest diameter (at least one lesion with any degree of dysplasia). (Note: no restriction on the length of time that patients have had one or more existing lesions)
  • Willing to provide blood and tissue from diagnostic biopsies
  • Any smoking history is permitted. A history of prior or current tobacco use is not an exclusion criteria. While discouraged, patients are permitted to continue tobacco use while on the study.
  • Age 18 years or older
  • ECOG performance status ≤ 2 (Karnofsky ≥60%, see Appendix A)
  • Participant must have normal organ and marrow function as defined below within 21 days prior to study registration:

    • leukocytes ≥3,000/mcL
    • absolute neutrophil count ≥1,000/mcL
    • platelets ≥100,000/mcL
    • total bilirubin ≤2.0 g/dL
    • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
    • creatinine within normal institutional limits OR
    • creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
  • Ability to understand and the willingness to sign a written informed consent document
  • Women of childbearing potential (WOCBP) must agree to use appropriate method(s) of contraception. WOCBP should plan to use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of hcg) at screening. Pregnancy test will be repeated on the day of the first dose of study drug (before administration), although results of this test are not required for registration.
  • "Women of childbearing potential (WOCBP)" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
  • Men who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception

Exclusion Criteria:

  • Known carcinoma in situ (CIS) or invasive squamous cell carcinoma of the oral cavity. A history of a prior stage III (T1-2N1, T3N0) or IV (T1-3N2, T4N0) invasive head & neck squamous cell carcinoma treated with surgery and radiation with or without chemotherapy. Patients with prior locoregionally advanced tumors treated with surgery alone are eligible.
  • Existing significant autoimmune conditions. Patients with a history of Hashimoto thyroiditis who are stable on replacement hormone therapy are not excluded. Patients cannot be on long-term (> 4 weeks) corticosteroids at doses exceeding prednisone 20 mg (or its equivalent) prior to enrollment. Short-term corticosteroid dosing is permitted as long as steroids are discontinued within 2 weeks of study registration.
  • Subject who has had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Subject who has been treated with immunotherapy. This includes prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Known human immunodeficiency virus carrier or a diagnosis of immunodeficiency.
  • Any positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus, e.g., Hepatitis B surface antigen (HBsAg, Australia antigen) positive, or Hepatitis C antibody (anti-HCV) positive (except if HCV-RNA is negative).
  • A personal history of hematopoietic stem cell or solid organ transplant.
  • Known non-infectious pneumonitis or any history of interstitial lung disease.
  • A personal history of other active malignancies, with the exception of non-melanomatous skin cancers, low-risk prostate adenocarcinoma on active surveillance, or treated cancers in remission for the last 5 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03692325


Contacts
Layout table for location contacts
Contact: Glenn Hanna, MD 617-632-3090 gjhanna@partners.org
Contact: Alessandro Villa, DDS,PhD,MPH 617-732-5517 avilla@bwh.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Glenn Hanna, MD    617-632-3090    gjhanna@partners.org   
Contact: Alessandro Villa, DDS,PhD,MPH    617-732-5517    avilla@bwh.harvard.edu   
Principal Investigator: Glenn Hanna, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Glenn Hanna, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Glenn J. Hanna, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03692325     History of Changes
Other Study ID Numbers: 18-387
First Posted: October 2, 2018    Key Record Dates
Last Update Posted: January 24, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukoplakia
Leukoplakia, Oral
Precancerous Conditions
Neoplasms
Pathological Conditions, Anatomical
Mouth Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Mouth Diseases
Stomatognathic Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents